Promomed: Rivaroxaban (a drug that reduces the risk of thrombosis)

Main article: Platelets

2024: Completion of additional studies of Rivaroxaban

On October 28, 2024, the Promomed Group announced the completion of additional studies and the introduction into large-scale production of an optimized technology for deep synthesis and separation of substance for Rivaroxaban. The substance - from the production of the molecule to the finished product - was produced in industrial volumes at the plant of the Biochemist group in Saransk. At the same plant, the Group also produces the finished dosage form, film-coated tablets, in all necessary dosages.

Ensuring the uninterrupted availability of highly effective drugs for the prevention and treatment of thrombosis and other diseases of the cardiovascular system is an important task. pharmaceutical industries Rivaroxaban is a priority drug for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism, its effect is aimed at reducing the frequency of development, strokes heart attacks systemic thromboembolic complications and deaths caused by these diseases.

Drug substance (API) properties are a critical parameter for quality assurance of the drug product. Technological parameters, for example, product purity, directly affect the stability of the dosage form and the safety of therapy. Promomed specialists have developed and implemented an optimized production technology for Rivaroxabana API, which allows achieving the required quality parameters and increasing the availability of a vital drug.

We continue research activities aimed at developing innovative technologies for the synthesis of molecules and the production of substances, expand the range of products localized in a full cycle, and have all the necessary capacities for large-scale import substitution and meeting the needs of the state in the most important drugs. The release of Rivaroxaban was a natural continuation of the systemic work of Promomed to provide the country with medicines for the treatment of socially significant diseases, said the operating director of JSC "Biochemist" Alexander Rudko.